The Effect of Temperature and Perfusion Time on Response, Toxicity, and Survival in Patients with In-transit Melanoma Metastases Treated with Isolated Limb Perfusion

• Published in: Annals of surgical oncology Vol. 25; no. 7; pp. 1836 - 1842
• Main Authors: Katsarelias, Dimitrios, Rådbo, Erik, Ben-Shabat, Ilan, Mattsson, Jan, Olofsson Bagge, Roger
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2018; Springer Nature B.V
• Subjects: acute regional toxicity; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating - administration & dosage; Cancer and Oncology; Cancer och onkologi; chemotherapy; Chemotherapy, Cancer, Regional Perfusion - mortality; Extremities; Female; Femur; Follow-Up Studies; Humans; Kirurgi; Lymphatic Metastasis; Male; malignant-melanoma; Medical prognosis; Medicine; Medicine & Public Health; Melanoma; Melanoma - drug therapy; Melanoma - mortality; Melanoma - pathology; Melanoma, Cutaneous Malignant; Melanomas; Melphalan; Melphalan - administration & dosage; Metastases; Metastasis; Middle Aged; Multivariate analysis; Oncology; Perfusion; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Skin Neoplasms - drug therapy; Skin Neoplasms - mortality; Skin Neoplasms - pathology; Skin Neoplasms - secondary; Surgery; Surgical Oncology; Survival; Survival Rate; Temperature; Temperature effects; Toxicity; Tumors; Young Adult; Overall Response (OR); Perfusate Temperature; Local Toxicity; Perfusion Time; Isolated Limb Perfusion (ILP)
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-018-6459-9

Background Isolated limb perfusion (ILP) is used to treat in-transit metastases of melanoma of the extremities when surgical excision is not possible. The optimal setting concerning temperature and perfusion time is unknown. The purpose of this study was to analyze these factors concerning their effects on response, toxicity, and survival. Methods A retrospective analysis of 284 consecutive stage III melanoma patients treated with melphalan ILP for the first time in our institution, during a 31-year period (July 1986–May 2017), was performed. Our series was divided in four time periods, according to perfusion temperature and duration. Demographical data, stage, number, and size of lesions were retrieved from our prospective database. Results Overall response (OR) rate 83% and a complete response (CR) rate of 59%. Significant predictive factors for CR in multivariate analysis were non-bulky tumor, fewer metastases, and a perfusion time of 120 min. Predictive factors for increased local toxicity were femoral ILP and higher perfusion temperatures. The median overall survival was 30 months, and the independent negative prognostic factors were lymph-node status, bulky tumors, response, upper limb perfusion, and 120 min perfusion at 39–40 °C. Conclusions Modern ILP uses diminished perfusion time and lower temperature, leading to a decrease in toxicity. However, our data also show a decrease in response, which indicates that optimal perfusion time and temperature regimen remain to be determined.